MY132507A - Process for substituted pyridines - Google Patents

Process for substituted pyridines

Info

Publication number
MY132507A
MY132507A MYPI97005396A MYPI9705396A MY132507A MY 132507 A MY132507 A MY 132507A MY PI97005396 A MYPI97005396 A MY PI97005396A MY PI9705396 A MYPI9705396 A MY PI9705396A MY 132507 A MY132507 A MY 132507A
Authority
MY
Malaysia
Prior art keywords
amino
formula
substituted pyridines
nitro
processes
Prior art date
Application number
MYPI97005396A
Other languages
English (en)
Inventor
Keith Michael Devries
Robert Lee Dow
Stephen Wayne Wright
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MY132507A publication Critical patent/MY132507A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
MYPI97005396A 1996-11-14 1997-11-12 Process for substituted pyridines MY132507A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3088096P 1996-11-14 1996-11-14

Publications (1)

Publication Number Publication Date
MY132507A true MY132507A (en) 2007-10-31

Family

ID=21856496

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI97005396A MY132507A (en) 1996-11-14 1997-11-12 Process for substituted pyridines

Country Status (32)

Country Link
US (1) US6291489B1 (US06291489-20010918-C00045.png)
EP (1) EP0938476B1 (US06291489-20010918-C00045.png)
JP (1) JP3510635B2 (US06291489-20010918-C00045.png)
KR (1) KR20000053314A (US06291489-20010918-C00045.png)
CN (1) CN1237160A (US06291489-20010918-C00045.png)
AP (1) AP805A (US06291489-20010918-C00045.png)
AR (1) AR010584A1 (US06291489-20010918-C00045.png)
AT (1) ATE319687T1 (US06291489-20010918-C00045.png)
AU (1) AU4634697A (US06291489-20010918-C00045.png)
BG (1) BG103393A (US06291489-20010918-C00045.png)
BR (1) BR9712951A (US06291489-20010918-C00045.png)
CA (1) CA2270386C (US06291489-20010918-C00045.png)
CO (1) CO4930261A1 (US06291489-20010918-C00045.png)
DE (1) DE69735433D1 (US06291489-20010918-C00045.png)
EA (1) EA199900375A1 (US06291489-20010918-C00045.png)
GT (1) GT199700118A (US06291489-20010918-C00045.png)
HR (1) HRP970612A2 (US06291489-20010918-C00045.png)
ID (1) ID18898A (US06291489-20010918-C00045.png)
IL (1) IL129688A0 (US06291489-20010918-C00045.png)
IS (1) IS5029A (US06291489-20010918-C00045.png)
MA (1) MA24401A1 (US06291489-20010918-C00045.png)
MY (1) MY132507A (US06291489-20010918-C00045.png)
NO (1) NO992296D0 (US06291489-20010918-C00045.png)
OA (1) OA11044A (US06291489-20010918-C00045.png)
PA (1) PA8441401A1 (US06291489-20010918-C00045.png)
PE (1) PE10299A1 (US06291489-20010918-C00045.png)
TN (1) TNSN97172A1 (US06291489-20010918-C00045.png)
TR (1) TR199901063T2 (US06291489-20010918-C00045.png)
UY (1) UY24774A1 (US06291489-20010918-C00045.png)
WO (1) WO1998021184A1 (US06291489-20010918-C00045.png)
YU (1) YU22099A (US06291489-20010918-C00045.png)
ZA (1) ZA9710186B (US06291489-20010918-C00045.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002511460A (ja) * 1998-04-08 2002-04-16 ノバルティス アクチエンゲゼルシャフト 新規除草剤
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
CA2362070A1 (en) 1999-02-16 2000-08-24 Masaru Mitsuda Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active .beta.3 agonist by the use of the same
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
DE60015036T2 (de) * 1999-07-23 2006-03-02 Pfizer Products Inc., Groton Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste
US20040265991A1 (en) * 2001-10-17 2004-12-30 Naoaki Taoka Process for preparation of (s)-alpha-halomethylpyridine-methanol derivatives
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
AU2003209527A1 (en) * 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
BR0307996A (pt) 2002-02-27 2004-12-07 Pfizer Prod Inc Processos e intermediários úteis na preparação de receptores de agonistas beta3-adrenérgicos
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
JP4454622B2 (ja) 2003-05-09 2010-04-21 エフ.ホフマン−ラ ロシュ アーゲー アルファ−1アドレナリン作動性アゴニストとしてのメチルインドール及びメチルピロロピリジン
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
WO2010068311A1 (en) 2008-05-23 2010-06-17 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
US5019578A (en) 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
PL312005A1 (en) 1993-06-14 1996-04-01 Pfizer Binary amines as antidiabetic and antiobesitic agents
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
JPH11504648A (ja) 1995-05-10 1999-04-27 ファイザー・インコーポレーテッド β−アドレナリン作動性アゴニスト
MX9708621A (es) * 1995-05-10 1998-02-28 Pfizer AGONISTAS beta-ADRENERGICOS, COMPOSICIONES QUE LOS CONTIENEN Y USO DE LOS MISMOS.

Also Published As

Publication number Publication date
CA2270386C (en) 2004-08-03
BG103393A (en) 2000-07-31
US6291489B1 (en) 2001-09-18
PA8441401A1 (es) 2000-05-24
IS5029A (is) 1999-04-16
KR20000053314A (ko) 2000-08-25
ID18898A (id) 1998-05-20
UY24774A1 (es) 1998-05-05
EP0938476A1 (en) 1999-09-01
AP9701147A0 (en) 1998-01-31
OA11044A (en) 2002-02-20
TNSN97172A1 (fr) 2005-03-15
CO4930261A1 (es) 2000-06-27
CA2270386A1 (en) 1998-05-22
HRP970612A2 (en) 1998-08-31
WO1998021184A1 (en) 1998-05-22
NO992296L (no) 1999-05-12
AU4634697A (en) 1998-06-03
CN1237160A (zh) 1999-12-01
GT199700118A (es) 1999-05-05
DE69735433D1 (de) 2006-05-04
PE10299A1 (es) 1999-02-10
TR199901063T2 (xx) 1999-08-23
JP3510635B2 (ja) 2004-03-29
AP805A (en) 2000-01-28
MA24401A1 (fr) 1998-07-01
EA199900375A1 (ru) 1999-12-29
EP0938476B1 (en) 2006-03-08
ZA9710186B (en) 1999-05-12
NO992296D0 (no) 1999-05-12
ATE319687T1 (de) 2006-03-15
IL129688A0 (en) 2000-02-29
BR9712951A (pt) 1999-12-07
AR010584A1 (es) 2000-06-28
JP2000504347A (ja) 2000-04-11
YU22099A (sh) 2001-09-28

Similar Documents

Publication Publication Date Title
MY132507A (en) Process for substituted pyridines
TW364903B (en) Halogenopyrimidines
PL328726A1 (en) Novel tricycle compounds, method of obtaining them and their applications
MX9701893A (es) Nuevos inhibidores de la prostaglandinsintasa.
NZ315400A (en) Pyridazin-3-one derivatives, their use, and intermediates for their production
MXPA04001323A (es) Dihidro-3-halo-1h-pirazol-5-carboxilatos sustituidos, su preparacion y uso.
AU1180797A (en) Phenylimidazolidines and use thereof as an antiandrogenic agent
YU78303A (sh) Postupak za dobijanje 1,3-supstituisanih indena i azapolicikličnih jedinjenja sa pripojenim arilom
DE69511260D1 (en) Bicyclische amidinderivate als no-synthetase inhibitoren
HUT43943A (en) Herbicide compositions comprising urea derivatives as active substance and process for preparing such compounds
MXPA03001972A (es) Derivados de 2-pirimidiniloxi-n-aril-bencilamina, procedimiento para su preparacion y usos de tales derivados.
DK0787124T3 (da) Fremgangsmåde til fremstilling af substituerede 3-aminobenzonitriler
ES530632A0 (es) Un procedimiento para preparar 2(1h)-piridinonas
TW349942B (en) Substituted 2-phenylpyridines, compositions containing same, processes for preparing same and their uses
GB9325618D0 (en) New herbicides
MX9700938A (es) Preparacion de acidos sacarincarboxilicos y esteres de acido carboxilico.
TW429253B (en) Novel pyrazole compounds
DK0873327T3 (da) Fremgangsmåde til fremstilling af 2-chlor-5-chlormethyl-thiazol
WO2003024400A3 (en) Process for the preparation of 1,5-diarylpyrazoles
MX9701569A (es) Pirimidin(tio)onas substituidas.
MXPA02001406A (es) Heterociclilos-2h-cromenos substituidos.
ZA200005110B (en) Process for preparing intermediates.
AU5674894A (en) Azanoradamantanes
DE50001717D1 (en) Herbizide substituierte thienocycloalk(en)ylamino-1,3,5-triazine
GR3029590T3 (en) Crystalline, polymorphic form of (s,s,s)-n-(1- 2-carboxy-3-(n?2 -mesyllysylamino)propyl]-1-cyclopentylcarbonyl)tyrosine